Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Leukemia, Myeloid, Chronic-Phase 22Leukemia 21Gastrointestinal Stromal Tumors 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasms 8Blast Crisis 7Neoplasm Metastasis 6Philadelphia Chromosome 4Myeloproliferative Disorders 4Melanoma 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Colorectal Neoplasms 2Substance Withdrawal Syndrome 1Sarcoma 1Retroperitoneal liposarcoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Peritoneal Neoplasms 1Neurofibromatoses 1

Interventions

avapritinib 4midostaurin 3masitinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Dasatinib 1Cladribine 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mastocytosis, Systemic × nilotinib × Clear all
NCT00109707 2021-06-29

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Novartis

Phase 1/2 Completed
507 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡